Objective        To observe the efficacy of different doses of statin in acute coronary syndrome (ACS)patients at acute phase.       Methods        Clinical data of 133 ACS patients (110 males and 23 females) hospitalized in our department from January 2012 to June 2014 were collected and retrospectively analyzed. These patients were divided into 4 groups

that is

group A (treated with rosuvastatin of 10 mg/d

n=32)

group B (20 mg/d rosuvastatin

n=37)

group C (20 mg/d atorvastatin

n=33)

and group D (40 mg/d atorvastatin

n=31). The serum levels of total cholesterol (TC)

low-density lipoprotein cholesterol (LDL-C)

high density lipoprotein cholesterol (HDL-C)

and non-high-density lipoprotein cholesterol (non-HDL-C)

and the incidences of adverse reactions were compared in each group before and in 6 to 8 weeks after the treatment

and among different groups.       Results      Before the treatment

there was no significant difference in the baseline data among the 4 groups (P0.05). After 6 to 8 weeks’ treatment

the serum levels of TC

LDL-C and non-HDL-C were dropped significantly in all groups (P0.01). After treatment

the level of △LDL-C and △non-HDL-C (the changes before and after the treatment) were significantly larger in groups B and D than groups A and C (P0.01)

but there was no significant difference in the 2 indexes between group B and group D (P0.05). During the treatment

only 1 patient from group B had significant increase in ALT

from 33 to 1120 U/L. And there was no report of adverse reactions in other groups.       Conclusion        High-dose statin (rosuvastatin 20 mg/d and atorvastatin 40 mg/d）treatment is superior to conventional-dose statin (rosuvastatin 10 mg/d and atorvastatin 20 mg/d) on the patients at acute phase of ACS

and has good safety at the same time.